The GUCY1A1 gene (Guanylate Cyclase 1 Soluble Subunit Alpha 1) encodes the α₁ subunit of soluble guanylate cyclase (sGC), a key enzyme in the nitric oxide (NO)-cGMP signaling pathway. sGC serves as the primary receptor for NO in the brain, catalyzing the conversion of GTP to cyclic GMP (cGMP), which acts as a ubiquitous second messenger regulating numerous cellular processes including vasodilation, synaptic plasticity, platelet aggregation, and neuronal survival. The α₁β₁ heterodimer (GUCY1A1 + [GUCY1B1](/genes/gucy1b1)) represents the primary form of sGC expressed in the brain and vascular endothelium, making it a critical nexus for NO-mediated signaling in both physiological and pathological states. [@buche2020]
Gene Information
<div class="infobox infobox-gene"> | Property | Value | |----------|-------| | Gene Symbol | GUCY1A1 | | Full Name | Guanylate Cyclase 1 Soluble Subunit Alpha 1 | | Chromosomal Location | 4q31.3 | | NCBI Gene ID | 2982 | | OMIM ID | 139396 | | Ensembl ID | ENSG00000147854 | | UniProt ID | Q02108 | | Protein Class | Enzyme - Guanylate cyclase | | Aliases | GUCY1A1, sGC-α1, GUCY1A, α1-sGC | | Gene Family | Soluble guanylate cyclase subunits (GUCY1A1, GUCY1B1) | </div>
Protein Structure and Function
Structure
The GUCY1A1 protein (~619 amino acids) contains several key structural domains:
...
GUCY1A1 Gene
Introduction
The GUCY1A1 gene (Guanylate Cyclase 1 Soluble Subunit Alpha 1) encodes the α₁ subunit of soluble guanylate cyclase (sGC), a key enzyme in the nitric oxide (NO)-cGMP signaling pathway. sGC serves as the primary receptor for NO in the brain, catalyzing the conversion of GTP to cyclic GMP (cGMP), which acts as a ubiquitous second messenger regulating numerous cellular processes including vasodilation, synaptic plasticity, platelet aggregation, and neuronal survival. The α₁β₁ heterodimer (GUCY1A1 + [GUCY1B1](/genes/gucy1b1)) represents the primary form of sGC expressed in the brain and vascular endothelium, making it a critical nexus for NO-mediated signaling in both physiological and pathological states. [@buche2020]
Gene Information
<div class="infobox infobox-gene"> | Property | Value | |----------|-------| | Gene Symbol | GUCY1A1 | | Full Name | Guanylate Cyclase 1 Soluble Subunit Alpha 1 | | Chromosomal Location | 4q31.3 | | NCBI Gene ID | 2982 | | OMIM ID | 139396 | | Ensembl ID | ENSG00000147854 | | UniProt ID | Q02108 | | Protein Class | Enzyme - Guanylate cyclase | | Aliases | GUCY1A1, sGC-α1, GUCY1A, α1-sGC | | Gene Family | Soluble guanylate cyclase subunits (GUCY1A1, GUCY1B1) | </div>
Protein Structure and Function
Structure
The GUCY1A1 protein (~619 amino acids) contains several key structural domains:
Heme domain: N-terminal region that binds the heme prosthetic group required for NO sensing (though heme binding is primarily to the β₁ subunit)
Dimerization domain: Central region mediates heterodimer formation with GUCY1B1
Catalytic domain: C-terminal region that converts GTP to cGMP through a cyclization reaction
GUCY1A1 forms a functional heterodimer with the β₁ subunit (encoded by [GUCY1B1](/genes/gucy1b1)) to create the catalytically active sGC enzyme. This heterodimer is the primary form of sGC expressed in the brain and vascular endothelium. The physical proximity of the GUCY1A1 and GUCY1B1 genes on chromosome 4q31.3 suggests potential co-regulation at the transcriptional level. [@friebe2017]
Function
Soluble guanylate cyclase is activated by:
Nitric oxide (NO): NO binds to the heme moiety of sGC, inducing a conformational change that activates catalytic activity. This is the primary physiological activation mechanism
Heme-independent mechanisms: Certain sGC stimulators (e.g., cinaciguat, riociguat, vericiguat) can activate sGC independently of NO by binding directly to the catalytic domain
The production of cGMP from GTP initiates downstream signaling cascades through:
cGMP-dependent protein kinases (PKG): PKG I and II phosphorylate numerous targets including transcription factors, ion channels, and synaptic proteins
cGMP-gated ion channels: CNGA1, CNGA2 subunits regulate calcium homeostasis
cGMP-regulated phosphodiesterases (PDE): PDE1, PDE2, PDE3, PDE5 regulate cGMP levels and crosstalk with cAMP signaling
Expression Pattern
GUCY1A1 is expressed in multiple tissue types throughout the body:
Brain Expression
Vascular endothelium: Throughout the cerebral vasculature, particularly in capillary endothelial cells
Neurons: Particularly in hippocampal pyramidal neurons and cortical pyramidal cells (layer 5)
Astrocytes: Bergmann glia in cerebellum and protoplasmic astrocytes in cortex
Microglia: Resting microglia show constitutive expression
Expression is highest during development and decreases with aging, which may contribute to age-related neurodegeneration and reduced synaptic plasticity. [@gucya2020]
Role in Neurodegeneration
Alzheimer's Disease
The NO-cGMP pathway is implicated in several aspects of AD pathogenesis:
Amyloid-β toxicity: Aβ oligomers reduce sGC expression and activity in neurons, impairing cGMP-mediated neuroprotection. Restoring sGC activity protects against Aβ-induced synaptic dysfunction. Studies show decreased sGC expression in AD temporal cortex and hippocampus. [@modir2020]
Tau pathology: cGMP signaling modulates tau phosphorylation through GSK-3β. Dysregulated sGC activity may contribute to hyperphosphorylated tau accumulation and neurofibrillary tangle formation.
Neurovascular dysfunction: sGC in endothelial cells regulates cerebral blood flow and blood-brain barrier integrity. Impaired NO-sGC signaling contributes to neurovascular dysfunction in AD, including reduced cerebral blood flow and BBB breakdown. [@sand2019]
Synaptic plasticity: cGMP is essential for long-term potentiation (LTP) and memory formation. sGC dysfunction contributes to synaptic deficits in AD models. sGC stimulators have been shown to improve memory in animal models of AD. [@gomez2017]
Mitochondrial dysfunction: cGMP signaling modulates mitochondrial biogenesis and function through PGC-1α. sGC dysregulation may contribute to the energy deficits observed in AD neurons.
Neuroinflammation: sGC activation reduces microglial activation and pro-inflammatory cytokine production, potentially modulating the chronic neuroinflammation in AD.
Parkinson's Disease
In PD, sGC signaling is affected in multiple ways:
Dopaminergic neuron survival: NO-cGMP signaling protects [dopaminergic neurons](/cell-types/dopaminergic-neurons) from oxidative stress and mitochondrial dysfunction. sGC agonists have shown neuroprotective effects in PD models, preserving dopaminergic neurons in the substantia nigra. [@zhou2019]
Neuroinflammation: sGC activation reduces microglial activation and pro-inflammatory cytokine production. This may be relevant given the central role of neuroinflammation in PD progression.
Mitochondrial function: cGMP signaling modulates mitochondrial biogenesis and function. sGC dysregulation may contribute to mitochondrial dysfunction in PD.